



TORRENT PHARMACEUTICALS LTD.

Regd. Office : Torrent House, Off Ashram Road, Ahmedabad-380 009

STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31ST DECEMBER, 2006

(Rs. in lacs except per share data)

PARTICULARS	STANDALONE AUDITED RESULTS					CONSOLIDATED RESULTS				
	THREE MONTHS ENDED ON		NINE MONTHS ENDED ON		ACCOUNTING YEAR ENDED ON	THREE MONTHS ENDED ON		NINE MONTHS ENDED ON		ACCOUNTING YEAR ENDED ON
	31-12-2006	31-12-2005	31-12-2006	31-12-2005	31-03-2006	31-12-2006	31-12-2005	31-12-2006	31-12-2005	31-03-2006
					UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED		AUDITED
Sales (net of Sales Tax / VAT)	21235	18183	65716	57242	73038	33360	27283	95499	75295	100101
Less : Excise and similar duties collected	196	1318	1090	4440	5236	661	1651	2268	5309	6427
Net Sales	21039	16865	64626	52802	67802	32699	25632	93231	69986	93674
Other Operating Income	675	305	1213	1047	1395	893	813	2061	2058	3042
Net Sales & Income from Operations	21714	17170	65839	53849	69197	33592	26445	95292	72044	96716
Expenditure :										
(Increase)/Decrease in Stock in Trade	(895)	(1531)	(3040)	(1023)	(430)	870	(1788)	(4304)	(7242)	(6305)
Consumption of Raw/Packing Material	5720	6797	20244	18975	23656	5976	6815	20500	18993	23656
Purchase of Traded Goods	2793	1099	6531	2245	3211	5589	4518	16608	13579	16868
Staff Cost	2631	2025	8323	5599	7726	6067	4949	18714	12901	17977
Manufacturing & Other Expenses	4067	2944	10019	7683	10538	6719	4968	16898	11434	16344
Selling Expenses	1922	1947	6318	5223	6974	2493	3566	10623	8701	11728
Research & Development Expenses	1882	1312	5140	4307	5642	1882	1312	5140	4307	5642
Total Expenditure	18120	14593	53535	43009	57317	29596	24340	84179	62673	85910
Operating Profit before Interest, Depreciation & Amortization and Tax	3594	2577	12304	10840	11880	3996	2105	11113	9371	10806
Net Interest expense	613	199	1003	357	546	676	219	1228	400	614
Depreciation & Amortization	740	608	2215	1636	2366	867	638	2406	1728	2552
Operating Profit before Tax	2241	1770	9086	8847	8968	2453	1248	7479	7243	7640
Other Income	160	14	167	127	130	159	7	167	129	130
Profit before Tax and Exceptional Item	2401	1784	9253	8974	9098	2612	1255	7646	7372	7770
Provision for Taxation										
Current Tax	264	250	1017	845	684	262	256	1009	804	802
MAT Credit Entitlement	(264)	-	(1017)	-	(300)	(264)	-	(1017)	-	(300)
Deferred Tax	-	307	1003	1183	1067	-	309	989	1161	1167
Fringe Benefit Tax	49	70	192	194	258	49	70	192	194	258
Excess Provision of Tax of Earlier Years	-	-	-	-	-	-	-	-	-	(49)
Profit after Tax and before Exceptional Item	2352	1157	8058	6752	7389	2565	620	6473	5213	5892
Exceptional Item	-	-	-	-	(806)	-	-	-	-	(806)
Net Profit for the Period	2352	1157	8058	6752	6583	2565	620	6473	5213	5086
Paid-up Equity Share Capital (Face Value Rs.5 except for quarter & nine months comparative periods, Rs. 10)	4231	2116	4231	2116	4231	4231	2116	4231	2116	4231
Reserves excluding revaluation reserves	-	-	-	-	34021	-	-	-	-	30553
Basic & Diluted EPS for the period	2.78	1.37	9.52	7.98	7.78	3.03	0.73	7.65	6.16	6.01
Basic & Diluted EPS for the period on Profit after Tax adjusted for exceptional item	2.78	1.37	9.52	7.98	8.41	3.03	0.73	7.65	6.16	6.64
Aggregate of Public shareholding										
Number of shares	21919832				21919832					
Percentage of shareholding	25.91%				25.91%					

(A) Notes to Consolidated Unaudited Results :

- The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 24-Jan-07.
- The figures for the comparative periods, wherever necessary, have been regrouped to render them comparable with the figures for the current periods.
- a) The Company has consolidated the financial results of the following wholly owned subsidiaries :

Heumann Pharma GmbH & Co Generika KG	Germany
Torrent Do Brasil Ltda	Brazil
Zao Torrent Pharma	Russia
Torrent Pharma GmbH	Germany
Torrent Pharma Philippines Inc.	Philippines
Torrent Pharma Inc.	U.S.A
Torrent Pharma Japan Co. Ltd.	Japan
Laboratorios Torrent S.A. de C.V.	Mexico
Torrent Australasia Pty Ltd.	Australia
- b) The consolidation of subsidiaries has been done in accordance with Accounting Standard 21 (Consolidated Financial Statements) issued by the Institute of Chartered Accountants of India.
- The Company operates in a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Rs. Lacs

Particulars	Quarter Ended			Nine Monts Ended			Year Ended
	31-Dec-06	31-Dec-05	Growth%	31-Dec-06	31-Dec-05	Growth%	
Sales in India							
Branded Business	13727	10837	27%	43740	35490	23%	44446
Contract Manufacture	2847	3190	-11%	8931	9244	-3%	12435
Others	53	29	-	150	100	-	134
Total Sales in India (A)	16627	14056	18%	52821	44834	18%	57015
Sales Outside India (B)	16733	13227	27%	42678	30461	40%	43086
Total Sales (A+B)	33360	27283	22%	95499	75295	27%	100101
Less : Excise and similar duties	661	1651	-	2268	5309	-	6427
Net Sales	32699	25632	28%	93231	69986	33%	93674

Sales outside India includes Rs. 18786 lacs in the current nine months (Rs. 11179 lacs in comparative nine months) and Rs. 16884 lacs in the previous year pertaining to Heumann Pharma GmbH & Co Generika KG, Germany acquired on 04-Jul-05.

- The basic and diluted EPS for the comparative quarter and nine months is calculated on post-split and post-bonus shares basis to facilitate comparison.

(B) Notes to Stand-alone Audited Results :

- The above results were reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on 24-Jan-07. There is no qualification in the Auditors Report on this statement of financial results.
- The figures for the comparative periods, wherever necessary, have been regrouped to render them comparable with the figures for the current periods.
- The Company operates in a solitary business segment viz. pharmaceuticals, comprising mainly manufacture of branded formulations. A further breakdown of pharmaceutical sales is given below.

Rs. Lacs

Particulars	Quarter Ended			Nine Months Ended			Year Ended
	31-Dec-06	31-Dec-05	Growth%	31-Dec-06	31-Dec-05	Growth%	
Domestic Formulations	13727	10837	27%	43740	35490	23%	44446
Exports	4608	4127	12%	12895	12408	4%	16023
Contract Manufacture	2847	3190	-11%	8931	9244	-3%	12435
Others	53	29	-	150	100	-	134
Gross Sales	21235	18183	17%	65716	57242	15%	73038
Less : Excise duty	196	1318	-	1090	4440	-	5236
Net Sales	21039	16865	25%	64626	52802	22%	67802

Domestic formulations sales for the comparative nine months and financial year 2005-06 includes the spill over sales due to postponement of purchases by the trade channel on account of uncertainties prevailing during March 2005 in respect of implementation of Value Added Tax in lieu of Sales Tax by certain State Governments.

- Effective financial year 2006-07, the Company implemented Accounting Standard (AS) 15 (Revised 2005) dealing with Employee Benefits, issued by the Institute of Chartered Accountants of India. Pursuant to the adoption, the additional obligations of the Company prior to 1-Apr-06, amounting to Rs 216 lacs (net of deferred tax asset of Rs 90 lacs) has been charged off to the General Reserve Account.
- The basic and diluted EPS for the comparative quarter and nine months is calculated on post-split and post-bonus shares basis to facilitate comparison.
- During the quarter, 9 investor complaints were received and resolved. No complaints were pending either at the beginning or at the end of the quarter.

For **TORRENT PHARMACEUTICALS LIMITED**

Place : Ahmedabad
Date : 24-Jan-07

... Visit us at www.torrentpharma.com...

sd/-
SAMIR MEHTA
Managing Director